Zymeworks (ZYME) Stock Price

Zymeworks Price

NYSE·CLOSED
27.81
​
Market closed

Over the last 11 years Zymeworks grew revenue by 45.8% annually, reaching 105.97 M USD. For Zymeworks, the net margin of -76.6% is up versus -794.0% a few years ago. The consensus 12-month price target for Zymeworks is 46.00 USD, about 65.4% above where the stock trades today. Of 19 analysts, 18 rate the stock a buy — an overall Buy consensus.

Zymeworks stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Zymeworks business model & stock analysis

Zymeworks, Inc. generates revenue through its clinical-stage biopharmaceutical products and platforms. The company develops biotherapeutics using its Azymetric bispecific platform, which creates antibodies binding multiple targets, and its ZymeLink ADC platform, combining cytotoxins with tumor-targeting antibodies. Lead product ZW25 targets HER2 for cancer treatment, while ZW49 integrates ZW25 design with ZymeLink for enhanced therapy. These products are developed for clinical trials and potential commercialization, with revenue expected from future partnerships or sales once approved. Zymeworks focuses on oncology and immune modulation, leveraging its EFECT platform for immune cell recruitment control. The company’s platforms and product candidates are designed for pharmaceutical partnerships, with potential buyers including biopharmaceutical firms seeking innovative cancer therapies. Revenue streams will emerge from licensing agreements, milestone payments, and future product sales once clinical development progresses. The company’s product pipeline includes ZW25 and ZW49, both targeting HER2-related cancers. ZW25 uses Azymetric technology, while ZW49 incorporates ZymeLink for antibody-drug conjugates. These are developed for potential commercialization, with revenue anticipated from biopharmaceutical partners who license these technologies or products for further development and marketing.

Frequently asked questions about Zymeworks

Analysts currently set an average price target of 43.40 USD for the Zymeworks stock (median: 46.00 USD), implying +56.1 % versus the latest price. The consensus is based on 19 analyst ratings.

19 analysts currently rate the Zymeworks stock: 18 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Zymeworks to generate revenue of 296.44 M USD and earnings per share of 1.04 USD.

Converted at the current exchange rate, the Zymeworks share trades at 24.79 EUR (27.81 USD).

The Zymeworks share (ZYME) is listed on 4 stock exchanges, including: NYSE (ZYME), Frankfurt (0OX.F), München (0OX.MU), Düsseldorf (0OX.DU).

The expected revenue of Zymeworks is 296.44 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Zymeworks is 78.19 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Zymeworks is currently 26.80. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Zymeworks stock.

The price-to-sales ratio (P/S) of Zymeworks is currently 7.07. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Zymeworks stock.

The Eulerpool Quality Score for Zymeworks is 2/10.

The ISIN of Zymeworks is US98985Y1082. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Zymeworks is A2DP0F. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Zymeworks is ZYME. The ticker symbol is used to trade Zymeworks shares on the stock exchange.

Fair ValueTerminal
23.36 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
401,382.58 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Currency
USD
Initial public offering
Apr 28, 2017
ISIN
US98985Y1082
Cusip
98985W102
Sedol
BYQHPK7
Market capitalization
2.08 B USDMid Cap
52-Week Range
PEG
-1.49
P/E ratio
P/Ee 2026
26.62
P/Ee 2027
27.12
P/Ee 2028
62.26
P/Ee 2029
17.07
P/Ee 2030
11.99
P/Se
7.07
EV/EBIT
—
P/B Ratio
7.75
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-29.83 %
Last updated Oct 23, 2026, 8:54 PM

Zymeworks Ticker

DÜSSELDORF · 0OX.DUFRANKFURT · 0OX.FMUNICH · 0OX.MUNEW YORK · ZYME

All fundamentals and in-depth analysis of Zymeworks

Our stock analysis for Zymeworks stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Zymeworks. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.